Plain-English translation of NCT04423211 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing a new approach for men whose prostate cancer has come back after surgery. The trial combines standard radiation therapy to the prostate area with a new medication called , which helps block cancer growth. For some men whose scans show cancer has spread beyond the pelvis, doctors will also target those spots with additional radiation.
After prostate surgery, cancer sometimes returns and starts growing again. Current standard treatment doesn't always work well enough for all men. This trial is testing whether adding this medication and targeted radiation to problem areas can stop the cancer from progressing longer and help men live better lives.
You likely qualify if…
You likely don't qualify if…
You'll start with a special PET scan to see where your cancer is located. Depending on the results, you'll be randomly assigned to one of four treatment groups. All participants receive six months of radiation to the prostate area, plus hormone injections or pills. Some groups also receive the new medication for an extended period, and some may receive additional targeted radiation to any cancer spots outside the pelvis. You'll have regular visits to monitor your health, blood tests, and imaging scans over many months to see how well the treatment works.
AI-generated summary from trial data · Aug 29, 2026 · Not medical advice
United States